Samit Hirawat's most recent trade in Pacira BioSciences Inc was a trade of 10,891 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pacira BioSciences Inc | Samit Hirawat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2026 | 10,891 | 10,891 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Samit Hirawat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2026 | 6,405 | 6,405 (0%) | 0% | 0 | Common Stock | |
| Pacira BioSciences Inc | Samit Hirawat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2026 | 39,291 | 39,291 | - | - | Stock Option (Right to Buy) | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Purchase of securities on an exchange or from another person at price $ 47.58 per share. | 25 Apr 2025 | 4,250 | 83,513 (0%) | 0% | 47.6 | 202,215 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 52,720 | 52,720 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 35,146 | 35,146 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 28,593 | 99,040 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 28,593 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 10,545 | 88,495 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 9,232 | 79,263 (0%) | 0% | 63.1 | 582,632 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,854 | 73,929 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,854 | 11,711 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 4,886 | 68,818 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 4,886 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 4,765 | 4,767 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 4,765 | 70,919 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 2,484 | 70,447 (0%) | 0% | 63.1 | 156,765 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 2,327 | 66,154 (0%) | 0% | 63.1 | 146,857 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 2,013 | 68,075 (0%) | 0% | 63.1 | 127,040 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 998 | 72,931 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 831 | 70,088 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 337 | 68,481 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | Purchase of securities on an exchange or from another person at price $ 54.85 per share. | 14 Feb 2025 | 1,823 | 63,932 (0%) | 0% | 54.9 | 100,000 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 01 Nov 2024 | 1,830 | 62,109 (0%) | 0% | 54.7 | 100,055 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 60,952 | 60,952 | - | - | Performance Shares | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 40,635 | 40,635 | - | - | Market Share Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 29,311 | 80,256 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 29,311 | 0 | - | - | Performance Shares | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 10,203 | 70,053 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 9,774 | 60,279 (0%) | 0% | 53.8 | 525,743 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 5,854 | 17,565 | - | - | Market Share Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 4,885 | 4,886 | - | - | Market Share Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 4,885 | 53,855 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 4,765 | 9,532 | - | - | Market Share Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 4,192 | 0 | - | - | Market Share Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 4,192 | 51,437 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 2,068 | 50,945 (0%) | 0% | 53.8 | 111,238 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 1,807 | 48,970 (0%) | 0% | 53.8 | 97,199 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 842 | 53,013 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2024 | 660 | 50,777 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 01 Jul 2023 | 9,357 | 0 | - | - | Restricted Stock Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 01 Jul 2023 | 9,357 | 52,032 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 01 Jul 2023 | 4,787 | 47,245 (0%) | 0% | 64.0 | 306,129 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 35,129 | 35,129 | - | - | Performance Shares | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 25,139 | 54,035 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 25,139 | 0 | - | - | Performance Shares | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 23,419 | 23,419 | - | - | Market Share Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 14,429 | 42,675 (0%) | 0% | 65.7 | 948,130 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 4,885 | 9,771 | - | - | Market Share Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 4,885 | 28,601 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 4,765 | 14,297 | - | - | Market Share Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 4,765 | 31,259 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 4,189 | 4,192 | - | - | Market Share Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 4,189 | 25,481 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 3,069 | 57,104 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 2,909 | 26,494 (0%) | 0% | 65.7 | 191,150 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 2,540 | 23,716 (0%) | 0% | 65.7 | 166,903 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 2,517 | 28,896 (0%) | 0% | 65.7 | 165,392 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 802 | 29,403 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 775 | 26,256 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2023 | 154 | 31,413 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 01 Jul 2022 | 9,356 | 9,357 | - | - | Restricted Stock Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 01 Jul 2022 | 9,356 | 26,078 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 01 Jul 2022 | 4,786 | 21,292 (0%) | 0% | 76.8 | 367,756 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2022 | 28,593 | 28,593 | - | - | Performance Shares | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2022 | 19,062 | 19,062 | - | - | Market Share Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2022 | 4,885 | 18,953 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2022 | 4,885 | 14,656 | - | - | Market Share Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2022 | 4,189 | 8,381 | - | - | Market Share Units | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2022 | 4,189 | 15,941 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2022 | 2,779 | 16,722 (0%) | 0% | 68.4 | 190,139 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2022 | 2,426 | 14,068 (0%) | 0% | 68.4 | 165,987 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2022 | 553 | 16,494 (0%) | 0% | 0 | Common Stock, $0.10 par value | ||
| Bristol-Myers Squibb | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 10 Mar 2022 | 548 | 19,501 (0%) | 0% | 0 | Common Stock, $0.10 par value |